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Abstract: We have investigated histidine residues near the active site of the mitogenic Pasteurella multocida toxin. Muta-
tion of H1202 or H1228 had little effect, while the effect of mutation on H1223 depended on the amino acid substituted. 
Mutation of H1205 caused complete loss of activity, indicating its importance in PMT activity. 
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INTRODUCTION 
 The  Pasteurella multocida toxin (PMT) is a potent mito-
gen for fibroblasts [1]. PMT also affects bone cells, acting as 
a mitogen for osteoblasts and stimulating bone resorption in 
vitro [2-5]. PMT stimulates members of the Gq and G12 fami-
lies of heterotrimeric G-proteins [6-9], and these signalling 
proteins are thought likely to be the molecular targets of 
PMT. Their activation by PMT leads to numerous down-
stream sequelae including activation of phospholipase C 
[6,10] and Rho-linked signalling [11,12]. 
  PMT is the only toxin known to activate members of the 
Gq and G12 G-protein families and is thus likely to become a 
useful tool for studying pathways linked to these important 
signalling molecules. We have already used PMT to investi-
gate the function of tyrosine phosphorylation in the activa-
tion of Gq [8] and to identify the role of the Rho GTPase in 
osteoblast function [5]. 
  PMT is an intracellularly-acting toxin of 1285 amino 
acids (146 kDa), which comprises a receptor binding domain 
at the N-terminus, followed by a translocation domain, and 
an active domain at the C-terminus [13-15]. We have previ-
ously analysed the role of cysteine residues in the toxin 
molecule and identified an essential role for C1165 [16]. 
Mutation of this residue completely abrogated activity with-
out grossly affecting the toxin structure. Orth and co-workers 
subsequently suggested that 2 histidine residues within the 
same region (H1205 and H1223) were essential for activity 
[17]. Recently, Kitadokoro and co-workers have crystallised 
the C-terminal domain and suggest that it comprises 3 sub-
domains, including a domain (the C3 domain) that contains a 
catalytic triad that consists of C1165, H1205 and D1220 
(PDB identifier 2EBF) [18]. We have analysed the role of all 
4 histidine residues in the C3 subdomain and show here that 
H1205 is critical for activity, whereas mutation of H1223 has 
only a partial effect that is dependent on which amino acid 
replaces H1223. 
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MATERIALS AND METHODS 
Materials 
  All chemical reagents were from Sigma, Ltd., unless oth-
erwise stated. Oligonucleotides were synthesised by Sigma 
Genosys. Restriction endonucleases and other enzymes were 
purchased from Promega Corporation or New England Bio-
labs. Chromatography reagents and radioisotopes were pur-
chased from Amersham Bioscience unless stated otherwise. 
Bacterial Strains 
 Escherichia  coli XL1-Blue was the host for pTox2, which 
expresses full-length recombinant PMT (UniProt code 
http://www.expasy.org/sprot/userman.html - AC_line P17452) 
from its own promoter [16], and for pTox2 C-terminal dele-
tants and point mutants. E. coli strains were routinely cultured 
in Luria-Bertani (LB) broth or on LB agar aerobically (at 30 
oC for pGEX constructs or at 37 
oC for pTox2 and its deriva-
tives). Antibiotics were added as appropriate at the following 
concentrations; tetracycline, 20 μg ml
-1; and ampicillin, 100 
μg ml
-1. 
DNA Sequencing, Site Directed Mutagenesis 
  Plasmid DNA was isolated by using Wizard kits 
(Promega Corporation). For sequence analysis, DNA was 
further purified by using Qiaquick columns (Qiagen). DNA 
sequencing was performed with a Beckman CEQ2000 auto-
mated DNA sequencer. PMT histidine residues 1202, 1205, 
1223 and 1228 were replaced individually with leucine and 
with tyrosine using the Stratagene Quikchange system. 
Plasmid pTox2 [16], which encodes the native toxin, was 
used as the template for site-directed mutagenesis reactions 
using oligonucleotide primers of 25 nucleotides length de-
signed to generate the desired mutations. Two separate colo-
nies of each of the eight potential mutants were stored for 
further analysis. 
Purification and SDS-PAGE Analysis of Recombinant 
Proteins 
  PMT and untagged toxin derivatives were purified as 
previously described from cleared lysates by anion exchange 
chromatography followed by hydrophobic interaction chro-
matography [16]. Glycerol was added to 50 % (v/v), and 
preparations were stored at -20 
oC for up to 6 months. 
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Proteins were separated in denatured form on 4 % stacking 
and 8 % resolving gels [19]. Proteins were visualised by a 
silver staining technique as described previously [20]. 
Assays for PMT Activity 
  Swiss 3T3 fibroblasts were maintained as described in 
reference 1. DNA synthesis was measured by the incorpora-
tion of [
3H]thymidine into quiescent Swiss 3T3 cells as de-
scribed [21]. The cell-binding of PMT fragments was as-
sessed by determining their ability to compete with PMT in 
DNA synthesis assays as described previously [13]. For actin 
staining, cells were fixed in 3.7 % (w/v) formaldehyde in 
PBS for at least 10 min. This was followed by permeabilisa-
tion for 5 min in the presence of 0.5 % (v/v) Triton X-
100/PBS and blocking for 10 min with 1 % (w/v) BSA, 100 
mM glycine. Cells were then placed in 0.5 μg TRITC-
phalloidin ml
-1 for 30 min (each step was preceded by 3 
washes in PBS). Stained cells were washed and mounted in 
Vectashield (Vector Laboratories). Total inositol phosphates 
were assayed as described [22]. Briefly, [
3H]myo-inositol-
labeled Swiss 3T3 cells were pretreated with 17.5 pM PMT 
or mutants for 4.5 h. Inositol phosphates were prepared and 
expressed as cpm/well. 
Proteolysis 
  The susceptibility of PMT and its mutants to proteolysis 
by the serine protease Glu-C was assayed in the presence of 
different concentrations of SDS as previously described [23]. 
RESULTS 
  The four published sequences of the PMT gene show a 
high degree of conservation and the four histidine residues 
analysed here are conserved and in the same context in each 
sequence. Histidine point mutants of PMT (PMT
H1202L, 
PMT
H1205L, PMT
H1223L, PMT
H1228L, PMT
H1202Y, PMT
H1205Y, 
PMT
H1223Y and PMT
H1228Y) were prepared as described in 
Methods. Sequencing confirmed that at least one isolate of 
each had the desired mutation. The 8 mutant toxins were all 
expressed in similar amounts to wild-type PMT (not shown). 
The relative activities of these mutant toxins were assessed 
in a number of assays. The ability of purified toxins to in-
duce DNA synthesis in quiescent Swiss 3T3 cells was com-
pared with normal PMT. PMT
H1205L and PMT
H1205Y were 
completely inactive up to a concentration of 100 ng ml
-1, 
whilst wild-type toxin stimulated DNA synthesis at as little 
as 0.3 ng ml
-1 (Fig. 1). PMT
H1202Y was as active as wild type 
toxin, whereas PMT
H1228Y was attenuated about 3-fold. Inter-
estingly, PMT
H1223Y was around 30 times less active than 
wild-type toxin. For each of the 3 pairs of mutations, the 
associated leucine mutants were attenuated around a further 
30-50 fold compared to the tyrosine substitutions. This 
meant that PMT
H1223L was at least 1000-fold less active than 
wild-type PMT. 
  The effect of the amino acid substitutions on the ability 
to induce cytoskeletal rearrangements was determined. PMT 
induced the formation of thick, parallel stress fibres, whereas 
untreated cells contained disorganised actin fibres (Fig. 2A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Induction of DNA synthesis in quiescent Swiss 3T3 fibroblasts by PMT and mutants. The results are expressed as a percentage of 
the counts obtained following stimulation with 10 % foetal bovine serum. The results presented are the means and standard errors from six 
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Only the three histidine mutants that demonstrated the least 
activity in the thymidine incorporation assay, PMT
H1205L, 
PMT
H1205Y and PMT
H1223L, failed to induce actin stress fibre 
formation under these conditions. The effect of the mutations 
on the activation of Gq was tested by assessing the ability of 
the mutant toxins to stimulate production of inositol 
trisphosphate (IP3). PMT
H1205L, PMT
H1205Y and PMT
H1223L 
did not significantly induce inositol phosphate  formation 
(Fig. 2B), showing that they failed to activate Gq. The other 
mutants were all partially active. These results are summa-
rised in Table 1. 
  The three mutants with a marked reduction in activity 
were tested for proteolytic resistance to the protease Glu-C 
to determine whether these mutations had introduced gross 
structural changes that affected protein stability. We have 
previously shown that this technique can identify subtle   
differences in structure that are undetectable by circular   
dichroism [16]. The susceptibility of these mutant toxins was 
 
 
Table 1.  Relative Activity of PMT Mutants 
 
Mutant Mitogenicity Inositol trisphosphate 
induction 
Stress fibre 
formation 
H1202L   57 56  + 
H1205L   1 1  - 
H1223L   10 3  - 
H1228L   45 18  + 
H1202Y   96 98  ++ 
H1205Y   1 8  - 
H1223Y   52 23 +++ 
H1228Y  83 80 +++ 
Summary of data in Figs. 1 and 2. The values given for mitogenicity are the average of 
induced thymidine incorporation relative to that induced by 10% foetal calf serum at 1, 
10 and 100ngml
-1 PMT (Fig. 1). Inositol trisphosphate induction is the induction above 
the untreated value relative to that induced by 10% foetal calf serum (Fig. 2). The 
induction of stress fibres formation is scored on the basis of - no induction; + evidence 
of stress fibre formation; ++ between + and +++; +++ stress fibre induction equivalent 
to that induced by PMT (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Effects of histidine mutants of PMT. A On the formation of actin stress fibres in quiescent Swiss 3T3 cells. Toxins were added at 5 
ng ml
-1 for 16 h. Additions were as follows: (a), untreated; (b) PMT
H1202L; (c) PMT
H1205L; (d) PMT
H1223L; (e) PMT
H1228L; (f) PMT; (g) 
PMT
H1202Y; (h) PMT
H1205Y; (i) PMT
H1223Y; (j) PMT
H1228Y. B On the induction of inositol trisphosphates. Inositol phosphates were assayed in 
quiescent Swiss 3T3 cells that had been labelled with 
3H-inositol for 20 h, then treated for 4h with 20 ng ml
-1 mutant toxins or left untreated. 
The results were expressed as a percentage of the counts obtained for wild-type PMT. The bars represent the mean and standard errors for six 
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tested at a range of SDS concentrations as previously de-
scribed [23]. PMT
H1205Y became susceptible to proteolytic 
cleavage at the same SDS concentration as PMT (Fig. 3), 
suggesting that it was structurally unaltered. PMT
H1205L and 
PMT
H1223L were a little more sensitive to SDS denaturation, 
suggesting that they possessed slightly altered structures. 
  The inactive mutants PMT
H1205L and PMT
H1205Y were 
tested for their ability to bind to cells, using the competition 
assay to assess whether they could block the mitogenic activ-
ity of 2 ng PMT ml
-1. Each mutant significantly inhibited the  
 
mitogenic action of PMT when added to a concentration of 6 
μg ml
-1 or higher (Fig. 4). 
DISCUSSION 
  A critical role for histidine residues in PMT activity was 
first suggested by Orth and co-workers [17], who proposed 
that H1205 and H1223 were essential for PMT function. 
Kitadokoro and colleagues have recently suggested that 
C1165, H1205 and D1220 form a catalytic triad that might 
facilitate either proteolytic or acyltransferase activity [18], 
while H1223 faces away from the putative active site. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Resistance of PMT and selected histidine mutants to digestion with the protease, Glu-C. One microgram of PMT or mutant toxins 
was incubated with 25 ng Glu-C (Sigma) in the presence of different concentrations of SDS for 1 h at 37 
oC. The SDS concentrations used 
were: lane 1, no SDS; 2, 0.005 %; 3, 0.075 %; 4, 0.01 %; 5, 0.0125 %; 6, 0.015 %; 7, 0.02 %; 8, 0.025 %. Lane 9 contains toxin with no Glu-
C. The products were electrophoresed through 10 % SDS-PAGE gels, and detected by silver staining. The toxin bands of 146 kDa are shown 
for PMT, PMT
H1205L, PMT
H1205Y and PMT
H1223L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Blocking of PMT-induced DNA synthesis by PMT
H1205L and PMT
H1205Y. DNA synthesis was assayed in quiescent Swiss 3T3 cells 
with PMT at 2ng ml
-1 in the presence of an excess of the mutant toxins. Results are expressed as the percentage of counts obtained with 10 % 
foetal bovine serum. BSA was used as a control. The blocking proteins were: () PMT
H1205L; () PMT
H1205Y; () BSA. The results presented 
are the means and standard errors from six determinations at each point. Histidine Residues at the Active Site of the Pasteurella multocida Toxin  The Open Biochemistry Journal, 2007, Volume 1    11 
  We have analysed the role of all the histidine residues 
within the catalytic C3 domain and have shown here that 
H1223 does not have as critical a role in activity as H1205. 
Substitution of H1205 with either tyrosine or leucine leads to 
complete loss of activity, without affecting cell binding ac-
tivity. In addition, the PMT
H1205Y substitution mutant shows 
little evidence of gross structural changes. We confirm that 
PMT
H1223L shows almost no activity in the most sensitive test 
of activity, the ability to induce thymidine incorporation, 
while the PMT
H1223Y mutant retained substantial but reduced 
activity (around 3% of the activity of wild-type toxin). Muta-
tion of the two other histidine residues in this region had 
little or no effect if tyrosine was substituted, although a sub-
stantially greater effect when replaced by leucine. This is 
probably due to the relatively conservative nature of the his-
tidine to tyrosine mutation, as both residues are polar and, 
aromatic. In contrast leucine is non-polar and smaller so is 
more likely to affect the structure of the toxin. We have 
shown here that leucine substitution leads to greater struc-
tural instability, as assessed by protease sensitivity. Simi-
larly, PMT
C1165S is more protease sensitive [16]. Structural 
analysis of the catalytic domain of PMT
C1165S has confirmed 
that it has a slightly altered structure, which correlates with 
the observed increase in protease sensitivity [18]. 
CONCLUSION 
  Taken together, H1202 and H1228 appear to play no di-
rect role in the PMT catalytic centre. Mutation of H1223 has 
a greater effect on activity, presumably because of its struc-
tural proximity to the catalytic centre, but our work supports 
the suggestion by Kitadokoro that H1223 is unlikely to be 
directly involved in catalysis [18]. The demonstration that 
mutation of H1205 has a major effect on PMT activity sup-
ports the concept that C1165, H1205 and D1220 are essential 
for catalysis. The identification of critical amino acid resi-
dues in the catalytic domain and the further definition of that 
domain should aid future studies on its function. 
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